Medicinal
chemistry plays a fundamental and underlying role in
chemical biology, pharmacology, and medicine to discover safe and
efficacious drugs. Small molecule medicinal chemistry relies on iterative
learning cycles composed of compound design, synthesis, testing, and
data analysis to provide new chemical probes and lead compounds for
novel and druggable targets. Using traditional approaches, the time
from hypothesis to obtaining the results can be protracted, thus limiting
the number of compounds that can be advanced into clinical studies.
This challenge can be tackled with the recourse of enabling technologies
that are showing great potential in improving the drug discovery process.
In this Perspective, we highlight recent developments toward innovative
medicinal chemistry strategies based on continuous flow systems coupled
with automation and bioassays. After a discussion of the aims and
concepts, we describe equipment and representative examples of automated
flow systems and end-to-end prototypes realized to expedite medicinal
chemistry discovery cycles.
Bile acids have been shown to inhibit human (h) carbonic anhydrases (CA, EC 4.2.1.1) along the gastrointestinal tract, including hCA II. The elucidation of the hormonal inhibition mechanism of the bile acid cholate to hCA II was provided in 2014 by X-ray crystallography. Herein, we extend the inhibition study to a wealth of steroids against four relevant hCA isoforms. Steroids displaying pendants and functional groups of the carboxylate, phenolic or sulfonate types appended at the tetracyclic ring were shown to inhibit the cytosolic CA II and the tumor-associated, transmembrane CA IX in a medium micromolar range (38.9-89.9 µM). Docking studies displayed the different chemotypes CA inhibition mechanisms. Molecular dynamics (MD) gave insights on the stability over time of hyocholic acid binding to CA II.
The modulation of FXR receptor remains an attractive area in drug discovery to develop novel therapeutic opportunities for liver and metabolic disorders. Despite the large variety of FXR ligands reported so far, only a very restricted number of agonists have entered in clinical settings. In this review article we provide the reader with an overview on the different classes of natural and synthetic ligands that have been developed by academic groups and pharmaceutical companies to target FXR. We discuss their structure-activity relationships, analyzing the binding modes that some of these compounds adopt to interact with the receptor.
Pregnane X receptor (PXR) is a master xenobiotic-sensing transcription factor and a
validated target for immune and inflammatory diseases. The identification of chemical
probes to investigate the therapeutic relevance of the receptor is still highly desired.
In fact, currently available PXR ligands are not highly selective and can exhibit
toxicity and/or potential off-target effects. In this study, we have identified
garcinoic acid as a selective and efficient PXR agonist. The properties of this natural
molecule as a specific PXR agonist were demonstrated by the screening on a panel of
nuclear receptors, the assessment of the physical and thermodynamic binding affinity,
and the determination of the PXR-garcinoic acid complex crystal structure. Cytotoxicity,
transcriptional, and functional properties were investigated in human liver cells, and
compound activity and target engagement were confirmed in vivo in mouse liver and gut
tissue. In conclusion, garcinoic acid is a selective natural agonist of PXR and a
promising lead compound toward the development of new PXR-regulating modulators.
Discovered as a modulator of the toxic response to environmental pollutants, aryl hydrocarbon receptor (AhR) has recently gained attention for its involvement in various physiological and pathological pathways. AhR is a ligand-dependent transcription factor activated by a large array of chemical compounds, which include metabolites of l-tryptophan (l-Trp) catabolism as endogenous ligands of the receptor. Among these, 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester (ITE) has attracted interest in the scientific community, being endowed with nontoxic, immunomodulatory, and anticancer AhR-mediated functions. So far, no information about the binding mode and interactions of ITE with AhR is available. In this study, we used docking and molecular dynamics to propose a putative binding mode of ITE into the ligand binding pocket of AhR. Mutagenesis studies were then instrumental in validating the proposed binding mode, identifying His 285 and Tyr 316 as important key residues for ligand-dependent receptor activation. Finally, a set of ITE analogues was synthesized and tested to further probe molecular interactions of ITE to AhR and characterize the relevance of specific functional groups in the chemical structure for receptor activity.
The discovery of lead compounds relies on the iterative generation of structure−activity relationship data resulting from the synthesis and biological evaluation of hit analogues. Using traditional approaches, a significant time delay may occur from compound design to results, leading to slow and expensive hit-to-lead explorations. Herein, we have exploited the use of chemical toolboxes to expedite lead discovery and optimization. In particular, the integration of flow synthesizers, automation, process analytical technologies, and computational chemistry has provided a prototype system enabling the multicomponent flow synthesis, in-line analysis, and characterization of chiral tetracyclic quinolines as a novel class of PXR agonists. Within 29 compounds, a novel template 19b (3aS,11R,11aS) was identified with an EC 50 of 1.2 μM (efficacy 119%) at the PXR receptor.
The integration of flow systems with statistical design of experiments is emerging as a valuable strategy to develop new synthetic routes towards relevant building blocks, chemical probes, and drug compounds. Optimization by experimental design incorporates statistical algorithms, mathematical models and equations, predicting tools, feedback control, and validation to generate new optimal conditions. Continuous-flow chemistry is ideally suited for this scope, as the integration of in-line analysis is simple; experimental parameters such as temperature, pressure, and flow rate can be easily controlled and fine-regulated; and automation of reaction screening can be accomplished with software assistance. This review article aims to illustrate how the combination of flow synthesizers and design of experiments can be profitable to speed up the development and optimization of more efficient, safer, and reproducible protocols for modern synthetic methods and manufacturing processes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.